Core Insights - INVL Baltic Sea Growth Fund has sold its entire stake in MBL Group to MidEuropa, marking the fund's second exit and enabling full repayment to investors [1][2] - MBL is a leading European contract development and manufacturing organization (CDMO) specializing in assisted mobility, rehabilitation, and aged-care equipment, with significant growth in EBITDA since INVL's investment [2][3] - The transaction is seen as a strong endorsement of MBL's business model and long-term potential, with the Lauritsen family reinvesting and Martin Lauritsen continuing as CEO [1][3] Company Overview - MBL, founded in 1988 by the Lauritsen family in Denmark, is the largest European CDMO for medical mobility devices, employing approximately 1,700 professionals across Europe and Asia [2][3] - The company has over 100 registered patents and is recognized for its innovation capabilities, with projected revenue exceeding EUR 120 million by 2025 [2][3] Investment Context - The assisted mobility market is expected to grow due to factors such as population aging and increasing prevalence of chronic conditions, which aligns with MBL's strategic focus [3] - MidEuropa, a leading European private equity investor, aims to support MBL's growth and international expansion, emphasizing the investment's strong fundamentals and long-term growth potential [3][6] Fund Background - INVL Baltic Sea Growth Fund, with a size of EUR 165 million, is one of the leading private equity funds in the Baltics, backed by the European Investment Fund [4] - The fund is managed by INVL Asset Management, which has over 30 years of experience and manages more than EUR 2 billion in various investment strategies [4][5] Transaction Details - The transaction was advised by Jefferies International, with legal, financial, and commercial support from Horten, Deloitte, and L.E.K. respectively [3]

NEW YORK, Dec. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Integer Holdings Corporation (NYSE: ITGR). Shareholders who purchased shares of ITGR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/integer-holdings-corporation-loss-submission-form/?id=180696&from=4 CLASS ...

Core Viewpoint - BioStem Technologies' products, VENDAJE® and VENDAJE AC®, have been granted a 12-month status quo period for reimbursement eligibility under the CMS CY 2026 Final Medicare Reimbursement Rule, ensuring continued access for patients with diabetic foot ulcers (DFU) and venous leg ulcers (VLU) [3][4]. Group 1: Reimbursement Status - The 12-month status quo designation allows BioStem's products to remain eligible for reimbursement in 2026, provided their use meets the "reasonable and necessary" standard [4]. - The Medicare Administrative Contractors (MACs) will review additional evidence by December 31, 2026, with updated determinations expected in early 2027 [4]. Group 2: Impact on Other Products - The final policy from CMS specifically applies to DFU and VLU indications, leaving reimbursement for other wound types, such as pressure ulcers, unaffected [5]. - Pressure ulcers represent the largest segment of the chronic wound market at 41%, which is crucial for BioStem's sales volume and Medicare-related revenue [5]. Group 3: Company Statements and Future Plans - The CEO of BioStem expressed appreciation for CMS's evidence-driven approach and anticipates uninterrupted payment for their products in DFU and VLU applications throughout 2026 [6]. - BioStem plans to engage with CMS and MACs to discuss clinical trial findings and aims to achieve reclassification of their products from Status Quo to Covered status during the 2027 reconsideration cycle [6].

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Integer Holdings Corporation (NYSE: ITGR). Shareholders who purchased shares of ITGR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/integer-holdings-corporation-loss-submission-form/?id=180542&from=3 CLA ...

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com, by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com. What Happened? LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased Integer Holdings Corporation ("Integer†or the "Company†) (NYSE: ITGR) common stock between July 25, 2024 and October 22, 2025, inclusive (the " ...

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Integer Holdings Corporation (NYSE: ITGR) between July 25, 2024 and October 22, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 9, 2026. SO WHAT: If you purchased Integer common stock during the Class ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly making materially false and misleading statements regarding its competitive position and sales performance in the electrophysiology manufacturing market during the specified Class Period from July 25, 2024, to October 22, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Integer overstated its competitive position in the electrophysiology manufacturing market and mischaracterized its EP devices as long-term growth drivers for its cardio and vascular segment [5]. - It is alleged that Integer experienced a deterioration in sales for two of its EP devices, contradicting its claims of strong customer demand [5]. - The lawsuit asserts that the positive statements made by the defendants about Integer's business and prospects were materially false and misleading, leading to investor damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased Integer common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the court by February 9, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - A class action has been filed against Integer Holdings Corporation (ITGR) for allegedly misleading investors about the demand for its electrophysiology (EP) devices, which has reportedly declined significantly [2][3]. Group 1: Allegations and Market Position - The complaint claims that Integer Holdings Corporation misrepresented its market position in the growing EP market and overstated the demand for its EP devices [2]. - Contrary to the company's claims, demand for Integer's EP devices has significantly decreased, with revenue growth from these devices decelerating instead of outpacing market growth [2]. Group 2: Financial Guidance and Stock Impact - On October 23, 2025, Integer revised its full-year 2025 guidance, projecting net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026 [3]. - The company acknowledged that two of its EP devices faced slower-than-expected market adoption, which is anticipated to continue affecting demand into 2026 [3]. - Following this announcement, Integer's stock price dropped by $35.22 per share, a decline of over 32%, closing at $73.89 per share on the same day [3].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Integer Holdings Corporation (NYSE: ITGR) for the period between July 25, 2024, and October 22, 2025, due to alleged misleading statements regarding the company's competitive position and sales performance in the electrophysiology market [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Integer Holdings Corporation overstated its competitive position in the electrophysiology manufacturing market and mischaracterized its EP devices as long-term growth drivers for its cardio and vascular segment [5]. - It is alleged that Integer experienced a deterioration in sales related to two of its EP devices, contradicting its claims of strong visibility into customer demand [5]. - The lawsuit asserts that the positive statements made by the defendants about Integer's business and prospects were materially false and misleading, leading to investor damages when the true details became public [5]. Group 2: Participation Information - Investors who purchased Integer common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must file a motion with the court by February 9, 2026, to represent other class members in the litigation [1][3].

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Integer Holdings Corporation (NYSE: ITGR) between July 25, 2024 and October 22, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 9, 2026. SO WHAT: If you purchased Integer common stock during the Class ...